{"contentid": 488542, "importid": NaN, "name": "Lung cancer approval latest good news story for Tecentriq", "introduction": "European authorities have granted marketing authorization for a new indication for Tecentriq (atezolizumab), the checkpoint blocker developed by Roche.", "content": "<p><span style=\"font-weight: 400;\">European authorities have granted marketing authorization for a new indication for Tecentriq (atezolizumab), the checkpoint blocker developed by Roche (ROG: SIX).</span></p>\n<p><span style=\"font-weight: 400;\">The approval covers first-line treatment of certain people with non-small cell lung cancer (NSCLC), and comes around a year after the US regulator gave its blessing for this application of the therapy.</span></p>\n<p><span style=\"font-weight: 400;\">The decision was based on data from the Phase III IMpower110 study, which showed that Tecentriq monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy.</span></p>\n<h2><strong>Tecentriq development</strong></h2>\n<p><span style=\"font-weight: 400;\">First approved in 2016, Roche has invested heavily in broadening the use of its blockbuster immunotherapy, securing revenues of $2.9 billion in 2020. For the first quarter of 2021, sales grew strongly to $847 million.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The firm has ongoing and planned Phase III studies across different settings in lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">Analysts believe there is particular growth potential for checkpoint blockers in the adjuvant and neoadjuvant settings across different tumor types.</span></p>\n<p><span style=\"font-weight: 400;\">Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options, allowing administration every two, three or four weeks, providing a high degree of flexibility.</span></p>\n<p><span style=\"font-weight: 400;\">The treatment made headlines recently due to a review from the US Food and Drug Administration on Accelerated Approvals, the outcome of which was </span><a href=\"https://www.thepharmaletter.com/article/more-i-o-early-approvals-bear-scrutiny-of-fda-review\"><span style=\"font-weight: 400;\">reaffirmed support</span></a><span style=\"font-weight: 400;\"> for certain approvals in bladder cancer and breast cancer, despite a lack of confirmatory data.</span></p>\n<p><span style=\"font-weight: 400;\">Commenting on the recent regulatory news, chief medical officer Levi Garraway said: &ldquo;Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.&rdquo;</span></p>", "date": "2021-05-05 11:16:00", "meta_title": NaN, "meta_keywords": "Tecentriq, cancer, lung, Roche, checkpoint, treatment, approval, people, European, authorities, granted, marketing, authorization, indication, atezolizumab", "meta_description": "European authorities have granted marketing authorization for a new indication for Tecentriq (atezolizumab), the checkpoint blocker developed by Roche.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-05 11:16:19", "updated": "2021-05-05 11:31:34", "access": NaN, "url": "https://www.thepharmaletter.com/article/lung-cancer-approval-latest-good-news-story-for-tecentriq", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_roche_big.jpg", "image2id": "2020_roche_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "Europe, Switzerland", "company_tag": "Roche", "drug_tag": "Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-05 11:16:00"}